TwentyTwentyTweets
Tweets by 2020health-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: Pfizer
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?
Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading
Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research
Tagged 2020health, Abbott, alcohol, AstraZeneca, bribes, criminal, dishonest, Drugs, General practitioner, government, GP, GPs, GSK, innovation, Kuno Sommer, law breaking, life expectancy, Lilly, medicine, misleading, National Health Service, NHS, Obesity, patient, Patients, Paxil, Pfizer, pharmaceutical, practolol, pricing, R&D, Research, Responsibility in healthcare, Seroquel, thalidomide, tobacco, Wellbutrin, wrongdoing, Zhen Xiaoyu
Leave a comment
Political Mood Change over the NHS, Innovation and the Pharmaceutical Industry in 2011
As 2011 draws to a close now is a good time to reflect on the period since the last UK General Election in 2010. We must consider what we have done right, what we have done wrong and what remains … Continue reading
Posted in Business, David Cameron, Department of Health, Drugs, Election, Genetics, Health Bill, Health Team, Hospitals, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, David Cameron, Department of Health, Drugs, genetics, government, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Pills, pricing and growth
Warfarin, toxin of choice to rid us of nasty rats, is also the drug of choice to stop you having a blood clot. Liberally prescribed on the NHS, the tablets cost peanuts. However it’s not perfect. You can’t take it … Continue reading
Posted in Business, Drugs, Innovation, Uncategorized
Tagged BMS, George Osborne, Germany, National Health Service, Pfizer, pricing, warfarin
Leave a comment
Guest Blogspot – The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines
The UK Government yesterday published its detailed response to the three-month public consultation concluded in March 2011 on value-based pharmaceutical pricing. The Government has emphasised that work on the proposals is still at an early stage. The mistake made with … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Employment, Finance, Innovation, NHS, Patients, Pharma, Policy, Research
Tagged 2020health, Alzheimer's Disease, Andrew Dillon, Andrew lansley, Department of Health, Drugs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, patient access, Patients, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspote: How to encourage pharmaceutical R&D
Politicians should only attempt the possible. We must recognise what we cannot do. The UK Government alone cannot influence the direction of R&D significantly. The sums of money involved are so vast that R&D only makes sense in a global … Continue reading
Posted in Andrew Lansley, Business, competition, Department of Health, Drugs, Health Bill, Hospitals, Innovation, NHS, Pharma, Policy, Research, Uncategorized, White Paper
Tagged 2020health, Andrew lansley, biotechnology, breakthrough, Clinical trials, competition, Department of Health, Equity and Excellence, health, Health Bill, medicine, National Health Service, NHS, NICE, patent box, Pfizer, pharmaceutical, pricing, R&D, R&D tax credit, Research, university, value-based, value-based pricing, wholesaler
Leave a comment
Pfizer closure a blow to science and growth confidence
Whilst Pfizer are saying that their closure of their Kent-based research site is due to internal changes in priorities it highlights both fundamental changes in the approach to drug research and development (R&D) and the urgent need for the UK … Continue reading
Posted in Drugs, Pharma
Tagged Clinical trials, Growth, Kent, medicines, Pfizer, pharmacueticals
Leave a comment
Smart Pfizer and compulsory MMR
The Wall Street Journal yesterday highlighted how smart Pfizer had been in acquiring the vaccines manufacturer Wyeth. With the blockbuster business model for pharma having been on the wane for some time, it’s been imperative for all pharma to develop … Continue reading
2020health's Blog 
You must be logged in to post a comment.